nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—NEK11—cerebellum—attention deficit hyperactivity disorder	0.0533	0.0828	CbGeAlD
Dabrafenib—LIMK1—midbrain—attention deficit hyperactivity disorder	0.0493	0.0766	CbGeAlD
Dabrafenib—NEK11—brain—attention deficit hyperactivity disorder	0.0433	0.0672	CbGeAlD
Dabrafenib—SIK1—forebrain—attention deficit hyperactivity disorder	0.0386	0.06	CbGeAlD
Dabrafenib—LIMK1—cerebellum—attention deficit hyperactivity disorder	0.0382	0.0592	CbGeAlD
Dabrafenib—LIMK1—brain—attention deficit hyperactivity disorder	0.031	0.0481	CbGeAlD
Dabrafenib—RAF1—forebrain—attention deficit hyperactivity disorder	0.0308	0.0477	CbGeAlD
Dabrafenib—BRAF—midbrain—attention deficit hyperactivity disorder	0.0305	0.0473	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—attention deficit hyperactivity disorder	0.026	0.0404	CbGeAlD
Dabrafenib—BRAF—cerebellum—attention deficit hyperactivity disorder	0.0236	0.0366	CbGeAlD
Dabrafenib—SIK1—nervous system—attention deficit hyperactivity disorder	0.021	0.0326	CbGeAlD
Dabrafenib—RAF1—midbrain—attention deficit hyperactivity disorder	0.0203	0.0315	CbGeAlD
Dabrafenib—SIK1—central nervous system—attention deficit hyperactivity disorder	0.0202	0.0313	CbGeAlD
Dabrafenib—SIK1—cerebellum—attention deficit hyperactivity disorder	0.0197	0.0306	CbGeAlD
Dabrafenib—BRAF—brain—attention deficit hyperactivity disorder	0.0192	0.0297	CbGeAlD
Dabrafenib—RAF1—nervous system—attention deficit hyperactivity disorder	0.0167	0.0259	CbGeAlD
Dabrafenib—RAF1—central nervous system—attention deficit hyperactivity disorder	0.0161	0.0249	CbGeAlD
Dabrafenib—SIK1—brain—attention deficit hyperactivity disorder	0.016	0.0249	CbGeAlD
Dabrafenib—RAF1—cerebellum—attention deficit hyperactivity disorder	0.0157	0.0244	CbGeAlD
Dabrafenib—RAF1—brain—attention deficit hyperactivity disorder	0.0128	0.0198	CbGeAlD
Dabrafenib—SLC22A6—brain—attention deficit hyperactivity disorder	0.0124	0.0192	CbGeAlD
Dabrafenib—SLC22A8—nervous system—attention deficit hyperactivity disorder	0.00971	0.0151	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—attention deficit hyperactivity disorder	0.00935	0.0145	CbGeAlD
Dabrafenib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.0084	0.013	CbGeAlD
Dabrafenib—SIK1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.0081	0.0228	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00784	0.022	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00761	0.0214	CbGpPWpGaD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00743	0.0209	CbGpPWpGaD
Dabrafenib—SLC22A8—brain—attention deficit hyperactivity disorder	0.00742	0.0115	CbGeAlD
Dabrafenib—ABCG2—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.00717	0.0202	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00709	0.0199	CbGpPWpGaD
Dabrafenib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.0065	0.0101	CbGeAlD
Dabrafenib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00627	0.00974	CbGeAlD
Dabrafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—attention deficit hyperactivity disorder	0.00612	0.0172	CbGpPWpGaD
Dabrafenib—RAF1—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.0057	0.016	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00558	0.0157	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00551	0.0155	CbGpPWpGaD
Dabrafenib—CYP2C8—brain—attention deficit hyperactivity disorder	0.00543	0.00843	CbGeAlD
Dabrafenib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.0053	0.00823	CbGeAlD
Dabrafenib—ABCG2—brain—attention deficit hyperactivity disorder	0.00528	0.00819	CbGeAlD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.00514	0.0144	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.00484	0.0136	CbGpPWpGaD
Dabrafenib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00481	0.00747	CbGeAlD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—CACNB2—attention deficit hyperactivity disorder	0.00469	0.0132	CbGpPWpGaD
Dabrafenib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00463	0.00719	CbGeAlD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.0046	0.0129	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—GABRQ—attention deficit hyperactivity disorder	0.00457	0.0129	CbGpPWpGaD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—CACNA1C—attention deficit hyperactivity disorder	0.00429	0.0121	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00428	0.012	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00426	0.012	CbGpPWpGaD
Dabrafenib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00414	0.00643	CbGeAlD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00407	0.0114	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00394	0.0111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00393	0.011	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00389	0.0109	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00386	0.0109	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00368	0.0104	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00355	0.00999	CbGpPWpGaD
Dabrafenib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00341	0.00529	CbGeAlD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.0034	0.00955	CbGpPWpGaD
Dabrafenib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00328	0.00509	CbGeAlD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00327	0.00919	CbGpPWpGaD
Dabrafenib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.0032	0.00497	CbGeAlD
Dabrafenib—LIMK1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00313	0.0088	CbGpPWpGaD
Dabrafenib—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00312	0.00877	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00309	0.00869	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.00309	0.00869	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00299	0.0084	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00296	0.00832	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00286	0.00803	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00277	0.0078	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00264	0.00743	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00263	0.0074	CbGpPWpGaD
Dabrafenib—ABCB1—brain—attention deficit hyperactivity disorder	0.0026	0.00404	CbGeAlD
Dabrafenib—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.0026	0.00732	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00254	0.00713	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00248	0.00698	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00246	0.00691	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STUB1—attention deficit hyperactivity disorder	0.0024	0.00676	CbGpPWpGaD
Dabrafenib—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00239	0.00672	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00234	0.00657	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00228	0.00642	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00226	0.00636	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00223	0.00627	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00219	0.00616	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00207	0.00582	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00207	0.00581	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00204	0.00572	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00198	0.00556	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00197	0.00555	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00191	0.00536	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00191	0.00536	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00189	0.00531	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00188	0.00529	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-2-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00185	0.0052	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00182	0.00512	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00175	0.00492	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00173	0.00487	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00173	0.00486	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00172	0.00483	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.0017	0.00478	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00167	0.00469	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00166	0.00468	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00165	0.00463	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.0016	0.0045	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00159	0.00447	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00158	0.00444	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00157	0.00442	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00156	0.00439	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00152	0.00426	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00151	0.00426	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.0015	0.00421	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00149	0.0042	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00147	0.00415	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00145	0.00409	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00142	0.00398	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00141	0.00396	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00139	0.00391	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00139	0.0039	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00137	0.00386	CbGpPWpGaD
Dabrafenib—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00137	0.00384	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00136	0.00384	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00136	0.00383	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00136	0.00383	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.00134	0.00378	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00133	0.00373	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00132	0.00371	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00132	0.0037	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.0013	0.00366	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—EP300—attention deficit hyperactivity disorder	0.00125	0.00351	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00123	0.00346	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00121	0.0034	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.0012	0.00337	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00119	0.00335	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00119	0.00334	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00118	0.00332	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00117	0.00328	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STUB1—attention deficit hyperactivity disorder	0.00111	0.00312	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00109	0.00306	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00108	0.00304	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00108	0.00303	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00108	0.00302	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00105	0.00295	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000996	0.0028	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000959	0.0027	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00093	0.00261	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000918	0.00258	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000915	0.00257	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000911	0.00256	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000877	0.00247	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.000859	0.00242	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STUB1—attention deficit hyperactivity disorder	0.000832	0.00234	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000814	0.00229	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000786	0.00221	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000782	0.0022	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000777	0.00219	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000775	0.00218	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STUB1—attention deficit hyperactivity disorder	0.000768	0.00216	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000766	0.00215	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00075	0.00211	CbGpPWpGaD
Dabrafenib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000734	0.00206	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000732	0.00206	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000726	0.00204	CbGpPWpGaD
Dabrafenib—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000721	0.00203	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.00072	0.00203	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00072	0.00202	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.000716	0.00201	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000716	0.00201	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000689	0.00194	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000668	0.00188	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000654	0.00184	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000642	0.0018	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000636	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00063	0.00177	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000601	0.00169	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000588	0.00165	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00058	0.00163	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000561	0.00158	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000547	0.00154	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000538	0.00151	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000535	0.0015	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000535	0.0015	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000533	0.0015	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000531	0.00149	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SNAP25—attention deficit hyperactivity disorder	0.000526	0.00148	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000526	0.00148	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000521	0.00146	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000506	0.00142	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000489	0.00138	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000482	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000464	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000462	0.0013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000454	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000453	0.00127	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000444	0.00125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000432	0.00121	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000428	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000418	0.00118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000411	0.00116	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000407	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000406	0.00114	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000396	0.00111	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000393	0.0011	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00039	0.0011	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000387	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000378	0.00106	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EP300—attention deficit hyperactivity disorder	0.000371	0.00104	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000369	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000364	0.00102	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000359	0.00101	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000359	0.00101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000357	0.001	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000354	0.000994	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000351	0.000986	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000347	0.000974	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000333	0.000935	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000333	0.000935	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000329	0.000924	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000327	0.00092	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000324	0.000911	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000323	0.000908	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000322	0.000905	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000314	0.000882	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000312	0.000877	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000304	0.000856	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000299	0.000841	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000287	0.000808	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000274	0.000771	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000274	0.000769	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000273	0.000769	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000266	0.000748	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000265	0.000745	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000261	0.000733	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000255	0.000717	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000253	0.000712	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000251	0.000707	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000249	0.000701	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000247	0.000694	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000244	0.000687	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000243	0.000683	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00024	0.000674	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000226	0.000636	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000223	0.000628	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.00022	0.000619	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000218	0.000612	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000216	0.000608	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00021	0.000589	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000206	0.000581	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000206	0.000581	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000203	0.000571	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000202	0.000567	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.0002	0.000563	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000189	0.000531	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00018	0.000506	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00018	0.000506	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000177	0.000498	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—attention deficit hyperactivity disorder	0.000171	0.000481	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000165	0.000464	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000165	0.000463	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000161	0.000451	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000157	0.000442	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000156	0.00044	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000144	0.000404	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000139	0.000391	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000137	0.000385	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—attention deficit hyperactivity disorder	0.000128	0.00036	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000125	0.000352	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000124	0.000349	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00012	0.000339	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00012	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—attention deficit hyperactivity disorder	0.000118	0.000333	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000111	0.000312	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000111	0.000312	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000109	0.000307	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000109	0.000306	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000108	0.000304	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000101	0.000285	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—attention deficit hyperactivity disorder	9.34e-05	0.000262	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.86e-05	0.000249	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	8.64e-05	0.000243	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.43e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.29e-05	0.000233	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	6.71e-05	0.000189	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	6.67e-05	0.000187	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	5.36e-05	0.000151	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	4.67e-05	0.000131	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.88e-05	8.1e-05	CbGpPWpGaD
